ライフサイエンスコーパス: bipolar depression

1 ntipsychotics have proven to be effective in bipolar depression.

2 gine is effective at treating and preventing bipolar depression.

3 efficacy of midday bright light therapy for bipolar depression.

4 n little research effort in the treatment of bipolar depression.

5 f action in the pharmacological treatment of bipolar depression.

6 djunctive bright light therapy at midday for bipolar depression.

7 ze treatment strategies for individuals with bipolar depression.

8 and/or release in mania and DAT blockade in bipolar depression.

9 bitor, infliximab, among 60 individuals with bipolar depression.

10 r or an antipsychotic in patients with acute bipolar depression.

11 lly offers improved outcomes for people with bipolar depression.

12 d six trials representing 1383 patients with bipolar depression.

13 d, placebo-controlled study of patients with bipolar depression.

14 macological treatment in treatment-resistant bipolar depression.

15 ceptor in vivo, and lower receptor number in bipolar depression.

16 effects in patients with treatment-resistant bipolar depression.

17 relates of manic symptoms during episodes of bipolar depression.

18 ving adjunctive antidepressant treatment for bipolar depression.

19 tability in patients receiving treatment for bipolar depression.

20 before starting antidepressant treatment in bipolar depression.

21 ef treatment in enhancing stabilization from bipolar depression.

22 n transporters are first-line treatments for bipolar depression.

23 lihood of remaining well after an episode of bipolar depression.

24 risperidone in improving treatment-resistant bipolar depression.

25 ns for the management of treatment-resistant bipolar depression.

26 ls of adjunctive antidepressant treatment of bipolar depression.

27 effective antidepressant among patients with bipolar depression.

28 ficacy of pramipexole in treatment-resistant bipolar depression.

29 enefit ratio for antidepressant treatment of bipolar depression.

30 are effective in the short-term treatment of bipolar depression.

31 tidepressants in the short-term treatment of bipolar depression.

32 udies have examined treatment strategies for bipolar depression.

33 yroid function will facilitate recovery from bipolar depression.

34 cols differ in efficacy between unipolar and bipolar depression.

35 ere remains a significant gap in research on bipolar depression.

36 Cycle acceleration occurred only in bipolar depression (25.6%), with new rapid cycling in 32

37 , 89 adults were included, including 27 with bipolar depression, 25 with unipolar depression, and 37

38 In bipolar depression accompanied by manic symptoms, antide

39 use at admission included epilepsy/seizure, bipolar depression, age group, and cognitive performance

40 iation included epilepsy/seizure indication, bipolar depression, age group, peripheral vascular disea

41 dimensions and factor structure of mania and bipolar depression and (2) longitudinal studies reportin

42 f antidepressant trials for 41 patients with bipolar depression and 37 with unipolar depression, simi

43 Unipolar/bipolar depression and a history of attempted suicide we

44 to determine the association of unipolar and bipolar depression and a history of attempted suicide wi

45 of competing options for treatment-resistant bipolar depression and assesses the effectiveness and sa

46 en fail to discriminate between unipolar and bipolar depression and identify individuals who will dev

47 Bipolar depression and major depressive disorder exhibit

48 hologically complex clinical state than pure bipolar depression and merit recognition as a distinct n

49 ped 50 sets of clinical vignettes reflecting bipolar depression and presented them to experts in bipo

50 been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controll

51 drome, Angelman syndrome, Turner's syndrome, bipolar depression and schizophrenia.

52 ganglia are consistent with MRS findings in bipolar depression and suggest that inflammatory cytokin

53 rations associated with unipolar depression, bipolar depression, and anxiety disorders.

54 ted in a subset of patients with unipolar or bipolar depression, anxiety-related disorders, and schiz

55 ine coexisting with otherwise full syndromal bipolar depression are associated with antidepressant tr

56 rticipants with bipolar mania (BM) (n = 30), bipolar depression (BD) (n = 30), bipolar euthymia (BE)

57 y differentiate unipolar depression (UD) and bipolar depression (BD) remain unidentified.

58 n patients with unipolar depression (UD) and bipolar depression (BD) using functional near-infrared s

59 e endogenous KYN pathway in individuals with bipolar depression (BD), as well as the relationship bet

60 nts with major depressive disorder (MDD) and bipolar depression (BD).

61 cated adults were recruited: 30 with current bipolar depression (BPD), 30 with current bipolar hypoma

62 Manic switching occurred only in bipolar depression but happened less in patients taking

63 Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania.

64 ans and patients to consider lamotrigine for bipolar depression, but also to be aware that concurrent

65 It is present in mania and bipolar depression, but data are equivocal for euthymia.

66 effective treatment for treatment-resistant bipolar depression, but no randomized controlled trials

67 re associated with reduced symptoms of acute bipolar depression, but the magnitude of benefit is smal

68 ntidepressants is widely used to treat acute bipolar depression, but their efficacy and safety remain

69 As bipolar depression can be clinically indistinguishable f

70 AChR availability (20%-38%) in subjects with bipolar depression compared with euthymic and control su

71 f-management, addressing treatment-resistant bipolar depression, deepening the understanding of patho

72 have been investigated for their efficacy in bipolar depression due to the reduced risk of mania indu

73 Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours)

74 diagnosed with major depressive disorder or bipolar depression, had a Montgomery- angstromsberg Depr

75 Existing therapies for bipolar depression have a considerable lag of onset of a

76 e episodes associated with bipolar disorder (bipolar depression) have not been well studied.

77 ctivity is associated with both unipolar and bipolar depression; however, the function of POase in th

78 ng found to be effective in the treatment of bipolar depression; however, their long term tolerabilit

79 In bipolar depression imaging studies show increased dopami

80 ine with that of placebo in the treatment of bipolar depression in adult outpatients stabilized on a

81 is not efficacious in the treatment of acute bipolar depression in patients receiving antimanic or mo

82 es associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adj

83 -resistant recurrent unipolar depression and bipolar depression, in long-term General Adult Psychiatr

84 e from the STEP-BD randomized trial for pure bipolar depression, in which adjunctive antidepressants

85 In bipolar depression, lurasidone was metabolically neutral

86 es in cholinergic signaling in subjects with bipolar depression may improve our understanding of its

87 em resting connectivity between unipolar and bipolar depression may reflect differential risk of mani

88 were genotyped in additional schizophrenia, bipolar, depression (n > 1600), and control (n > 950) co

89 eing investigated as possible treatments for bipolar depression: NMDA antagonists and indirect AMPA a

90 cing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had

91 chotics had higher discontinuation rates; in bipolar depression, olanzapine+fluoxetine worsened total

92 The occurrence of mania and bipolar depression over the following year was ascertain

93 Lower serotonin transporter BP(1) in bipolar depression overlaps with that observed in major

94 omized controlled trial of psychotherapy for bipolar depression, participants received up to 30 sessi

95 inical outcomes in patients with unipolar or bipolar depression receiving pharmacological, neurostimu

96 The study included 979 individuals with bipolar depression recently discharged from a psychiatri

97 While guidelines for treating patients with bipolar depression recommend discontinuing antidepressan

98 efited from a first-line treatment for acute bipolar depression recommended by the Canadian Network f

99 between treatment with an antidepressant and bipolar depression recurrence.

100 a, developing effective treatments for acute bipolar depression remain inadequate.

101 rations in serotonergic neurotransmission in bipolar depression remains scant.

102 In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effe

103 unipolar depression and treatment-resistant bipolar depression showed a similar pattern of neural ab

104 vothyroxine (L-T4) to standard treatment for bipolar depression shows promise, but the mechanisms und

105 Eighty-five patients with bipolar depression that was inadequately responsive to a

106 unipolar depression and treatment-resistant bipolar depression, the latter being the depressed phase

107 icacy and safety of (es)ketamine in treating bipolar depression, there has been little research effor

108 well-controlled clinical studies on RAADs in bipolar depression to expand treatment options and impro

109 ed study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatmen

110 are the risk of mania among individuals with bipolar depression treated or not treated with antidepre

111 studies involving subjects with unipolar or bipolar depression treated with parenteral doses of scop

112 Patients Eighteen subjects with DSM-IV bipolar depression (treatment-resistant).

113 Bipolar depression was associated with family history of

114 However, in contrast to our null hypothesis, bipolar depression was associated with preserved striata

115 Adjunctive treatment with antidepressants in bipolar depression was associated with substantial risks

116 Forty-eight patients with unipolar or bipolar depression were treated with a course of bifront

117 ns and specific subtypes of depression (e.g. bipolar depression) were excluded.

118 ficacy and safety of adjunctive modafinil in bipolar depression, which is often characterized by exce

119 ated our previous finding that patients with bipolar depression who received a single ketamine infusi

120 th TRD (17 with major depression and 15 with bipolar depression) who responded to ketamine infusion w

121 for SAD and DSM-III-R criteria for major or bipolar depression with seasonal pattern had their level

122 ized, double-blind trial in 60 patients with bipolar depression, with SWM as the primary outcome meas

123 e antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania.